Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week open-label study of omalizumab in Japanese children with allergic asthma
2015-003534-27Phase 3
- Sponsor
- Novartis
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of omalizumab in allergic asthma, sponsored by Novartis. Primary endpoint: Serum free IgE geometric mean at 24 weeks.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on 2015-003534-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003534-27.